Treatment results of chemoradiation therapy for localized aggressive lymphomas: a retrospective 20-year study
暂无分享,去创建一个
K. Ohtomo | H. Igaki | M. Kurokawa | K. Izutsu | H. Yamashita | K. Nakagawa | K. Shiraishi | S. Chiba | M. Tago | N. Nakamura
[1] T. Molina,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.
[2] M. Pfreundschuh,et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Chott,et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] H. Nakamine,et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin‐6 as independent predictors of prognosis in aggressive non‐Hodgkin's lymphoma , 2002, European journal of haematology.
[5] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[6] A. Bezjak,et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. , 2001, International journal of radiation oncology, biology, physics.
[7] H. Joensuu,et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.
[8] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[10] G. Bonadonna,et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Jagannath,et al. Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. , 1991, Blood.
[12] R. Arriagada,et al. The value of adjunctive radiotherapy when chemotherapy is the major curative method. , 1990, International journal of radiation oncology, biology, physics.
[13] J. Connors,et al. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Jagannath,et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. , 1989, Blood.
[15] G. Kerr,et al. Influence of therapy on local control and survival in stage I and II intermediate and high grade non-Hodgkin's lymphoma. , 1988, European journal of cancer & clinical oncology.
[16] S. Horning,et al. Combined modality therapy for stage I-II large cell lymphoma. , 1987, International journal of radiation oncology, biology, physics.
[17] M. Kaminski,et al. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. , 1986, Annals of internal medicine.
[18] V. Devita,et al. The effect of combined modality therapy on local control and survival. , 1986, International journal of radiation oncology, biology, physics.
[19] D. Rosenthal,et al. Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H. Hattori,et al. Radiochemotherapy for non‐Hodgkin's lymphoma in palatine tonsil , 1984, Cancer.
[21] W. Velasquez,et al. Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomas , 1984, Cancer.
[22] T. Miller,et al. Initial chemotherapy for clinically localized lymphomas of unfavorable histology. , 1983, Blood.
[23] E. Freireich,et al. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types , 1980, Cancer.
[24] G. Bonadonna,et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. , 1980, International journal of radiation oncology, biology, physics.
[25] Stephen E. Jones,et al. CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA , 1979, The Lancet.
[26] S. Donaldson,et al. Combined modality therapy in malignant lymphomas. , 1977, Cancer treatment reports.
[27] Roger Williams,et al. PARACETAMOL HEPATOXICITY , 1976, The Lancet.
[28] N. Ahmadloo,et al. Treatment results of tonsillar lymphoma: a 10-year experience , 2004, Annals of Hematology.
[29] T. Conroy,et al. Radiotherapy is unnecessary in elderly patients with localized agressive non Hodgkin's lymphoma: results of the LNH 93-4 study , 2002 .
[30] A. Avilés,et al. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. , 1996, European journal of cancer. Part B, Oral oncology.
[31] A. Kida,et al. Clinical analysis of malignant lymphomas of tonsils. , 1996, Acta oto-laryngologica. Supplementum.
[32] A. Piattelli,et al. Head and neck non-Hodgkin's lymphomas. , 1995, European journal of cancer. Part B, Oral oncology.